Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Blood transfusions and human recombinant erythropoietin in premature newborn infants.

Literature DB >> 8795362

Blood transfusions and human recombinant erythropoietin in premature newborn infants.

P Williamson¹, G Griffiths, D Norfolk, M Levene.

Abstract

Entities: Gene Species

Mesh：

Substances：

Year: 1996 PMID： 8795362 PMCID： PMC1061156 DOI： 10.1136/fn.75.1.f65

Source DB: PubMed Journal: Arch Dis Child Fetal Neonatal Ed ISSN： 1359-2998 Impact factor: 5.747

× No keyword cloud information.

20 in total

1. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors.

Authors: P Stanier; D L Taylor; A D Kitchen; N Wales; Y Tryhorn; A S Tyms
Journal: BMJ Date: 1989-10-07

Review 2. Iron, plasma antioxidants, and the 'oxygen radical disease of prematurity'.

Authors: J L Sullivan
Journal: Am J Dis Child Date: 1988-12

Review 3. Leucodepletion of blood products by filtration.

Authors: D R Norfolk; L M Williamson
Journal: Blood Rev Date: 1995-03 Impact factor: 8.250

4. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study.

Authors: M P Meyer; J H Meyer; A Commerford; F M Hann; A A Sive; G Moller; P Jacobs; A F Malan
Journal: Pediatrics Date: 1994-06 Impact factor: 7.124

5. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

Authors: A S Yeager; F C Grumet; E B Hafleigh; A M Arvin; J S Bradley; C G Prober
Journal: J Pediatr Date: 1981-02 Impact factor: 4.406

6. Double blind trial of recombinant human erythropoietin in preterm infants.

Authors: A J Emmerson; H J Coles; C M Stern; T C Pearson
Journal: Arch Dis Child Date: 1993-03 Impact factor: 3.791

7. A randomized, double-blind, placebo-controlled trial of recombinant erythropoietin in treatment of the anemia of bronchopulmonary dysplasia.

Authors: R K Ohls; D D Hunter; R D Christensen
Journal: J Pediatr Date: 1993-12 Impact factor: 4.406

8. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study.

Authors: V Soubasi; G Kremenopoulos; E Diamandi; C Tsantali; D Tsakiris
Journal: Pediatr Res Date: 1993-11 Impact factor: 3.756

9. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group.

Authors: R F Maier; M Obladen; P Scigalla; O Linderkamp; G Duc; G Hieronimi; H L Halliday; H T Versmold; G Moriette; G Jorch
Journal: N Engl J Med Date: 1994-04-28 Impact factor: 91.245

10. Volume of blood removed for analytical purposes during hospitalization of low-birthweight infants.

Authors: E Nexø; N C Christensen; H Olesen
Journal: Clin Chem Date: 1981-05 Impact factor: 8.327

7 in total

1. Effect of blood transfusion on lipid peroxidation in preterm infants.

Authors: S P Wardle; J Drury; R Garr; A M Weindling
Journal: Arch Dis Child Fetal Neonatal Ed Date: 2002-01 Impact factor: 5.747

2. Transient neutropenia may be a risk of treating preterm neonates with high doses of recombinant erythropoietin.

Authors: G Latini; E Rosati
Journal: Eur J Pediatr Date: 1998-05 Impact factor: 3.183

3. Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease.

Authors: G Griffiths; R Lall; S Chatfield; A Short; P Mackay; P Williamson; J Brown; M I Levene
Journal: Arch Dis Child Fetal Neonatal Ed Date: 1997-05 Impact factor: 5.747

Review 4. Promoting neuroregeneration after perinatal arterial ischemic stroke: neurotrophic factors and mesenchymal stem cells.

Authors: Nienke Wagenaar; Caroline G M de Theije; Linda S de Vries; Floris Groenendaal; Manon J N L Benders; Cora H A Nijboer
Journal: Pediatr Res Date: 2017-11-01 Impact factor: 3.756